Achiko Logo cropped.jpg
Achiko AG – Investor Briefing
07 juil. 2022 15h22 HE | Achiko AG
ZURICH, Switzerland, July 07, 2022 (GLOBE NEWSWIRE) -- Achiko AG (OTCQB: ACHKF, SIX: ACHI, ISIN CH0522213468) (“Achiko”, the “Company”), would like to invite investors and shareholders to a...
Achiko Logo cropped.jpg
Achiko AG Announces Annual Results for the Year Ended December 31, 2021
26 juin 2022 19h30 HE | Achiko AG
ZURICH, Switzerland, June 26, 2022 (GLOBE NEWSWIRE) -- Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) announces its financial results for the year ended December...
Achiko Logo cropped.jpg
Achiko AG Publication of Annual Report and Annual Financial Statements 2021 to Occur by June 6, 2022
31 mai 2022 07h30 HE | Achiko AG
ZURICH, Switzerland, May 31, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) announces that...
Achiko Logo cropped.jpg
Achiko AG Obtains CE Mark for AptameX™ Covid-19 Rapid Test
17 mai 2022 07h30 HE | Achiko AG
Registered AptameX and Has Obtained a CE Mark, Allowing the Product to Be Sold in 27 Countries in the EUAptameX Has Unique Performance Advantages Over Other Rapid Tests Through its Use of DNA...
Achiko Logo cropped.jpg
AptameX Production and Commercialization Update
28 avr. 2022 08h15 HE | Achiko AG
Company has commenced shipping and will book first sales in May 2022Reorganized production line able to meet stronger than expected demand for Achiko AG’s innovative DNA aptamer saliva-based rapid...
Achiko Logo cropped.jpg
Achiko AG Signs Major Marketing and Sales Agreement with World’s Largest Islamic Association for its AptameX Covid-19 Rapid Test
20 avr. 2022 07h45 HE | Achiko AG
Signed major deal with Pengurus Wilayah Nahdlatul Ulama DKI Jakarta, for the use of Covid-19 test AptameX in general assemblies and activities. Located primarily in Indonesia, Nahdlatul Ulama is the...
Achiko Logo cropped.jpg
Achiko Secures up to USD$12.6 Million Equity and Debt Financing Lines with RiverFort Over Three Years
20 avr. 2022 07h30 HE | Achiko AG
ZURICH, Switzerland, April 20, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) announces the...
Achiko Logo cropped.jpg
Achiko AG Production and Sales Update
03 mars 2022 07h30 HE | Achiko AG
Unique Chemistry with DNA Aptamers Completing Pre-Sales Validation TestingCompleting Pre-Sales Validation Testing in Indonesia ZURICH, Switzerland, March 03, 2022 (GLOBE NEWSWIRE) -- Ad...
Achiko Logo cropped.jpg
Achiko AG Research Paper and Commercialization Update
14 févr. 2022 07h30 HE | Achiko AG
Calibration study results now available in draft paper on medRxiv, a preprint platform for health sciences, as “DNA Aptamer Gold Nanoparticle Colorimetric Diagnostic Test Kit of Saliva Samples for...
Achiko Logo cropped.jpg
Achiko AG Announces Feature Article on “How We Get Back to Normal” with its AptameX™ Covid-19 Rapid Test Technology
18 janv. 2022 07h30 HE | Achiko AG
ZURICH, Switzerland, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) is pleased to announce a feature article in The Jakarta Post:...